



41

1636

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: 9/16/03

Jean C. Bah  
Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jacques Drouin, et al.  
Serial No.: 09/319,782  
Filed: April 19, 2000  
For: NUR-RE RESPONSE ELEMENT WHICH BINDS  
NUR NUCLEAR RECEPTORS AND METHOD OF  
USE THEREFOR  
Group Art Unit: 1636  
Examiner: K. Katcheves

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
SEP 25 2003  
TECH CENTER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, enclosed herewith is a list of documents which the Applicants in the above-identified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application.

Foreign Patents

WO 96/41169; Israel, et al.; December 19, 1996.

#### Other Documents

N. Auphan, et al., "Immunosuppression by Glucocorticoids: Inhibition of NF- $\kappa$ B Activity through Induction of I $\kappa$ B Synthesis," Science 270:286-290, 1995.

E. Caldenhoven, et al., "Negative Cross-Talk between RelA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids," Mol. Endocrinol. 9(4):401-412, 1995.

L E.-C. Cheng, et al., "Functional Redundancy of the Nur77 and Nor-1 Orphan Steroid Receptors in T-cell Apoptosis," EMBO J. 16(8):1865-1875, 1997.

J. Drouin, et al., "Glucocorticoid Receptor Binding to a Specific DNA Sequence is Required for Hormone-dependent Repression of Pro-opiomelanocortin Gene Transcription," Mol. Cell. Biol. 9(12):5305-5314, 1989.

J.H. Eberwine and J. L. Roberts, "Glucocorticoid Regulation of Pro-opiomelanocortin Gene Transcription in the Rat Pituitary," J. Biol. Chem. 259(4):2166-2170, 1984.

C.R. Egan, et al., "A Gut-to-pharynx/tail Switch in Embryonic Expression of the *Caenorhabditis elegans ges-1* Gene Centers on Two GATA Sequences," Dev. Biol. 170:397-419, 1995.

J.-P. Gagner and J. Drouin, "Opposite Regulation of Pro-opiomelanocortin Gene Transcription by

Glucocorticoids and CRH," Mol. Cell. Endocrinol. 40:25-32, 1985.

J.-P. Gagner and J. Drouin, "Tissue-specific Regulation of Pituitary Proopiomelanocortin Gene Transcription by Corticotropin-releasing Hormone, 3', 5'-Cyclic Adenosine Monophosphate, and Glucocorticoids," Mol. Endocrinol. 1(10):677-682, 1987.

J. Godowski, et al., "Glucocorticoid Receptor Mutants that are Constitutive Activators of Transcriptional Enhancement," Nature 325:365-368, 1987.

S. Heck, et al., "A Distinct Modulating Domain in Glucocorticoid Receptor Monomers in the Repression of Activity of the Transcription Factor AP-1," EMBO J. 13(17):4087-4095, 1994.

T. Heinzel, et al., "A Complex Containing N-CoR, mSin3 and Histone Deacetylase Mediates Transcriptional Repression," Nature 387:43-48, 1997.

A. Helmberg, et al., "Glucocorticoid-induced Apoptosis of Human Leukemic Cells is Caused by the Repressive Function of the Glucocorticoid Receptor," EMBO J. 14(3):452-460, 1995.

A.J. Horlein, et al., "Ligand-independent Repression by the Thyroid Hormone Receptor Mediated by a Nuclear Receptor Co-repressor," Nature 377:397-404, 1995.

M. Iwata, et al., "Rescue of Thymocytes and T cell Hybridomas from Glucocorticoid-induced Apoptosis by Stimulation via the T cell Receptor/CD3 Complex: A Possible *In Vitro* Model for Positive Selection of the T cell Repertoire," Eur. J. Pharmacol. 21:643-648, 1991.

Y. Kamei, et al., "A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors," Cell 85:403-414, 1996.

T.K. Kerppola, et al., "Fox is a Preferential Target of Glucocorticoid Receptor Inhibition of AP-1 Activity *In Vitro*," Mol. Cell. Biol. 13(6):3782-3791, 1993.

L.B. King, et al., "To Be or Not to Be: Mutually Antagonistic Death Signals Regulate Thymocyte Apoptosis," Int. Arch. All. Immunol. 105:355-358, 1994.

L.B. King, et al., "A Targeted Glucocorticoid Receptor Antisense Transgene Increases Thymocyte Apoptosis and Alters Thymocyte Development," Immunity 3:647-656, 1995.

H. König, et al., "Interference Between Pathway-specific Transcription Factors: Glucocorticoids Antagonize Phorbol Ester-induced AP-1 Activity without Altering AP-1 Site Occupation *In Vivo*," EMBO J. 11(6):2241-2246, 1992.

L. Nagy, et al., "Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase," Cell 89:373-380, 1997.

S.A. Onate, et al., "Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily," Science 270:1354-1357, 1995.

G. Poulin, et al., NeuroD1/ $\beta$ 2 Contributes to Cell-specific Transcription of the Proopiomelanocortin Gene," Mol. Cell. Biol. 17(11):6673-6682, 1997.

R.I. Scheinman, et al., "Role of Transcriptional Activation of I $\kappa$ B $\alpha$  in Mediation of Immunosuppression by Glucocorticoids," Science 270:283-286, 1995.

R.I. Scheinman, et al., Characterization of Mechanisms Involved in Transrepression of NF- $\kappa$ B by Activated Glucocorticoid Receptors," Mol. Cell. Biol. 15(2):943-953, 1995.

R. Sgonc, et al., "Simultaneous Determination of Cell Surface Antigens and Apoptosis," Trends Genet. 10:41-42, 1994.

No fees are believed necessary to enter this statement. However, if any fees are necessary please charge Deposit Account 17-0055.

Respectfully submitted,

Jacques Drouin, et al.

September 16, 2003

By: 

Jean C. Baker  
Reg. No. 35,433  
Quarles & Brady LLP  
411 East Wisconsin Avenue  
Milwaukee, WI 53202-4497  
(414) 277-5709





Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/319,782		
		Filing Date	April 19, 2000		
		First Named Inventor	Jacques Drouin		
		Group Art Unit	1636		
		Examiner Name	K. Katcheves		
Sheet	2	of	4	Attorney Docket Number	480848.90018

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	N. Auphan, et al., "Immunosuppression by Glucocorticoids: Inhibition of NF-(kappa)B Activity through Induction of I(kappa)B Synthesis," Science 270:286-290, 1995.	
	✓	E. Caldenhoven, et al., "Negative Cross-talk between RelA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids," Mol. Endocrinol. 9(4):401-412, 1995.	
	✓	L.E.-C. Cheng, et al., "Functional Redundancy of the Nur77 and Nor-1 Orphan Steroid Receptors in T-cell Apoptosis," EMBO J. 16(8):1865-1875, 1997.	
	✓	J.Drouin, et al., "Glucocorticoid Receptor Binding to a Specific DNA Sequence is Required for Hormone-dependent Repression of Pro-opiomelanocortin Gene Transcription," Mol. Cell. Biol. 9(12):5305-5314, 1989.	
	✓	J.H. Eberwine and J.L. Roberts, "Glucocorticoid Regulation of Pro-opiomelanocortin Gene Transcription in the Rat Pituitary," J. Biol. Chem. 259(4):2166-2170, 1984.	
	✓	C.R. Egan, et al., "A Gut-to-pharynx/tail Switch in Embryonic Expression of the Caenorhabditis elegans ges-1 Gene Centers on Two GATA Sequences," Dev. Biol. 170:-397-419, 1995.	
	✓	J.-P. Gagner and J. Drouin, "Opposite Regulation of Pro-opiomelanocortin Gene Transcription by Glucocorticoids and CRH," Mol. Cell. Endocrinol. 40:25-32, 1985.	
	✓	J.-P. Gagner and J. Drouin, "Tissue-specific Regulation of Pituitary Proopiomelanocortin Gene Transcription by Corticotropin-releasing Hormone, 3', 5'-Cyclic Adenosine Monophosphate, and Glucocorticoids," Mol. Endocrinol. 1(10):677-682, 1987.	
	✓	J. Godowski, et al., "Glucocorticoid Receptor Mutants that are Constitutive Activators of Transcriptional Enhancement," Nature 325:365-368, 1987.	
	✓	S. Heck, et al., "A Distinct Modulating Domain in Glucocorticoid Receptor Monomers in the Repression of Activity of the Transcription Factor AP-1," EMBO J. 13(17):4087-4095, 1994.	
	✓	T. Heinzl, et al., "A Complex Containing N-CoR, mSin3 and Histone Deacetylase Mediates Transcriptional Repression," Nature 387:43-48, 1997.	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5467767\_1.PDF





Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/319,782		
		Filing Date	April 19, 2000		
		First Named Inventor	Jacques Drouin		
		Group Art Unit	1636		
		Examiner Name	K. Katcheves		
Sheet	3	of	4	Attorney Docket Number	480848.90018

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	A. Helmborg, et al., "Glucocorticoid-induced Apoptosis of Human Leukemic Cells is Caused by the Repressive Function of the Glucocorticoid Receptor," EMBO J. 14(3):452-460, 1995.	
	✓	A.J. Horlein, et al., "Ligand-independent Repression by the Thyroid Hormone Receptor Mediated by a Nuclear Receptor Co-repressor," Nature 377:397-404, 1995.	
ESim	✓	M. Iwata, et al., "Rescue of Thymocytes and T cell Hybridomas from Glucocorticoid-induced Apoptosis by Stimulation via the T cell Receptor/CD3 Complex: A Possible In Vitro Model for Positive Selection of the T cell Repertoire," Eur. J. Pharmacol. 21:643-648, 1991.	
	✓	Y. Kamei, et al., "A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors," Cell 85:403-414, 1996.	
	✓	T.K. Kerppola, et al., "Fox is a Preferential Target of Glucocorticoid Receptor Inhibition of AP-1 Activity In Vitro," Mol. Cell. Biol. 13(6):3782-3791, 1993.	
Sim	✓	L.B. King, et al., "To Be or Not to Be: Mutually Antagonistic Death Signals Regulate Thymocyte Apoptosis," Int. Arch. All. Immunol. 105:355-358, 1994.	
	✓	L.B. King, et al., "A Targeted Glucocorticoid Receptor Antisense Transgene Increases Thymocyte Apoptosis and Alters Thymocyte Development," Immunity 3:647-656, 1995.	
	✓	H. Konig, et al., "Interference Between Pathway-specific Transcription Factors: Glucocorticoids Antagonize Phorbol Ester-induced AP-1 Activity without Altering AP-1 Site Occupation In Vivo," EMBO J. 11(6):2241-2246, 1992.	
	✓	L. Nagy, et al., "Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase," Cell 89:373-380, 1997.	
	✓	S.A. Onate, et al., "Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily," Science 270:1354-1357, 1995.	
	✓	G. Poulin, et al., "NeuroD1/(beta)2 Contributes to Cell-specific Transcription of the Proopiomelanocortin Gene," Mol. Cell. Biol. 17(11):6673-6682, 1997.	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5467767\_1.PDF



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/319,782		
		Filing Date	April 19, 2000		
		First Named Inventor	Jacques Drouin		
		Group Art Unit	1636		
		Examiner Name	K. Katcheves		
Sheet	4	of	4	Attorney Docket Number	480848.90018

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	R.I. Scheinman, et al., "Role of Transcriptional Activation of I(kappa)B(alpha) in Mediation of Immunosuppression by Glucocorticoids," Science 270:283-286, 1995.	
	✓	R.I. Scheinman, et al., "Characterization of Mechanisms Involved in Transrepression of NF-(kappa)B by Activated Glucocorticoid Receptors," Mol. Cell. Biol. 15(2):943-953, 1995.	
	✓	R. Sgonc, et al., "Simultaneous Determination of Cell Surface Antigens and Apoptosis," Trends Genet. 10:41-42, 1994.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.